Ocrevus® (Ocrelizumab) and Ocrevus Zunovo™ (Ocrelizumab and Hyaluronidase-Ocsq) – Commercial Medical Benefit Drug Policyopen_in_new

UnitedHealthcare covers Ocrevus and Ocrevus Zunovo for adult primary progressive MS and relapsing forms of MS but deems them unproven/not medically necessary for lupus nephritis, rheumatoid arthritis, and systemic lupus erythematosus. Coverage requires a documented diagnosis, no concurrent use of other disease‑modifying, B‑cell‑targeted, or lymphocyte‑trafficking therapies, dosing per FDA labeling, documentation of prior positive response for continuation, and authorizations are limited to no more than 12 months.

"Initial authorization is limited to no more than 12 months; continuation/renewal authorization is limited to no more than 12 months."

Sign up to see full coverage criteria, indications, and limitations.